Marinomed Biotech AG (VIE:MARI)
Austria · Delayed Price · Currency is EUR 11.00
+0.20 (1.85%)
Jun 5, 2026, 5:37 PM CET
Marinomed Biotech AG Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 7.69 | 4.75 | 9.06 | 11.28 | 11.63 |
Other Revenue | 0.27 | 0.05 | 0.34 | 0.47 | - |
| 7.96 | 4.79 | 9.4 | 11.74 | 11.63 | |
Revenue Growth (YoY) | 66.08% | -49.01% | -19.96% | 1.00% | 43.12% |
Cost of Revenue | 1.42 | 3.77 | 8.08 | 9.4 | 10.43 |
Gross Profit | 6.54 | 1.03 | 1.32 | 2.35 | 1.2 |
Selling, General & Admin | 4 | 4.83 | 5.05 | 5.13 | 4.83 |
Other Operating Expenses | 2.49 | 2.75 | 1.83 | 1.83 | 1.42 |
Operating Expenses | 6.8 | 8 | 7.34 | 7.63 | 6.86 |
Operating Income | -0.26 | -6.98 | -6.01 | -5.28 | -5.66 |
Interest Expense | -0.54 | - | -1.38 | -2.51 | -1.51 |
Interest & Investment Income | - | - | - | 0.04 | 0.06 |
Currency Exchange Gain (Loss) | - | 0 | 0 | - | - |
Other Non Operating Income (Expenses) | 0.02 | -7.89 | 0.04 | 1.11 | -0.04 |
EBT Excluding Unusual Items | -0.79 | -14.87 | -7.35 | -6.64 | -7.15 |
Merger & Restructuring Charges | 18.91 | - | - | - | - |
Gain (Loss) on Sale of Investments | 0 | - | - | - | - |
Gain (Loss) on Sale of Assets | 0 | 0 | 0 | - | - |
Asset Writedown | - | -0.65 | - | - | - |
Other Unusual Items | - | - | 0.99 | 0.24 | 1.45 |
Pretax Income | 18.12 | -15.52 | -6.36 | -6.39 | -5.69 |
Income Tax Expense | 0.11 | -0.1 | 0 | 0.01 | 0.2 |
Net Income | 18.02 | -15.42 | -6.37 | -6.4 | -5.89 |
Net Income to Common | 18.02 | -15.42 | -6.37 | -6.4 | -5.89 |
Shares Outstanding (Basic) | 2 | 2 | 2 | 1 | 1 |
Shares Outstanding (Diluted) | 2 | 2 | 2 | 1 | 1 |
Shares Change (YoY) | 3.46% | 17.14% | 1.29% | 1.56% | 0.31% |
EPS (Basic) | 9.79 | -8.67 | -4.19 | -4.27 | -3.99 |
EPS (Diluted) | 9.79 | -8.67 | -4.19 | -4.30 | -4.00 |
Free Cash Flow | -1.1 | -2.4 | -3.7 | -5.43 | -5.79 |
Free Cash Flow Per Share | -0.60 | -1.35 | -2.44 | -3.62 | -3.92 |
Gross Margin | 82.15% | 21.40% | 14.07% | 20.00% | 10.32% |
Operating Margin | -3.31% | -145.55% | -63.97% | -44.99% | -48.67% |
Profit Margin | 226.36% | -321.66% | -67.72% | -54.48% | -50.67% |
Free Cash Flow Margin | -13.82% | -50.08% | -39.37% | -46.24% | -49.75% |
EBITDA | 0.05 | -6.56 | -5.56 | -4.89 | -5.28 |
EBITDA Margin | 0.60% | -136.93% | -59.15% | -41.66% | -45.42% |
D&A For EBITDA | 0.31 | 0.41 | 0.45 | 0.39 | 0.38 |
EBIT | -0.26 | -6.98 | -6.01 | -5.28 | -5.66 |
EBIT Margin | -3.31% | -145.55% | -63.97% | -44.99% | -48.67% |
Effective Tax Rate | 0.58% | - | - | - | - |
Revenue as Reported | 19.46 | 0.1 | 1.49 | - | - |